SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts

Core Insights - Surmodics, Inc. (SRDX) reported adjusted earnings per share (EPS) of 6 cents for Q3 fiscal 2025, a significant improvement from a loss of 27 cents in the same quarter last year and better than the Zacks Consensus Estimate of a loss of 21 cents [1] - The company’s total revenues for the quarter were $29.6 million, reflecting a year-over-year decline of 2.6%, but exceeding the Zacks Consensus Estimate by 4.3% [2][4] - Surmodics has revised its fiscal 2025 revenue guidance, now expecting total revenues between $116.5 million and $118.5 million, which indicates a decrease of 8-6% compared to the previous fiscal year [12][13] Revenue Analysis - Total revenues included $0.0 million from SurVeil drug-coated balloon (DCB) license fees, down from $1.1 million in Q3 fiscal 2024, attributed to the completion of the TRANSCEND clinical trial [2][4] - Excluding SurVeil DCB license fees, total revenues increased by 1% year-over-year to $29.6 million [3] - The Medical Device segment reported sales of $22.2 million, a decrease of 4.9% from the previous year, while In Vitro Diagnostics (IVD) sales improved by 5.7% to $7.4 million [5][6] Segment Performance - Product sales were $16.8 million, down 4.6% year-over-year, while royalties and license fees totaled $9.7 million, a decline of 7.7% [7] - Research, development, and other revenues increased by 35.7% to $3.1 million [8] - The decrease in SurVeil DCB product sales revenues was $1.7 million year-over-year, primarily due to lower demand from Abbott, Surmodics' exclusive distribution partner [4] Margin and Expense Trends - Gross profit decreased by 4.1% year-over-year to $20.9 million, with a gross margin contraction of 116 basis points to 70.9% [9] - Selling, general, and administrative expenses rose by 6.8% to $17.8 million, while research and development expenses fell by 22.4% to $7.6 million [10] Financial Position - Surmodics ended Q3 fiscal 2025 with cash and cash equivalents of $26.3 million, down from $29.2 million at the end of the previous quarter [11] - Total long-term debt slightly increased to $29.67 million from $29.63 million [11] Future Guidance - The company anticipates a decrease of $3.6 million in SurVeil DCB license fee revenues for fiscal 2025, with no further recognition of these revenues after March 31, 2025 [14] - Adjusted loss per share for fiscal 2025 is now projected to be between 35 and 20 cents, an improvement from the previous outlook of 62 to 42 cents [15]